Analysts are weighing in on the clinical biopharmaceutical company Mast Therapeutics Inc (NYSEMKT:MSTX) and development stage company TG Therapeutics Inc (NASDAQ:TGTX), with positive ratings and views.
Mast Therapeutics Inc
Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Mast Therapeutics, as the company is on track to announce top-line data in the first-quarter of 2016 for vepoloxamer in sickle cell pain crisis.
Baral noted, “Blinded statistics to date are encouraging, showing data variability within trial powering assumptions. Blended primary endpoint values of time to discharge readiness (last opioid administration) were below placebo assumptions, which we conservatively view as incrementally positive.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ritu Baral has a total average return of 16.6% and a 46.5% success rate. Baral has a 15.5% average return when recommending MSTX, and is ranked #115 out of 3775 analysts.
All the 4 analysts polled by TipRanks rate Mast Therapeutics stock a Buy. With a return potential of 367%, the stock’s consensus target price stands at $2.33.
TG Therapeutics Inc
Brean Capital analyst Jonathan Aschoff came out with a research report on TG Therapeutics, reiterating a Buy rating and a $28 price target, as the company is expected to start testing its glycoengineered anti-CD20 antibody (TG-1101, ublituximab) in MS patients by YE15. The analyst believes that enthusiasm for this pursuit can only rise as the newly positive Roche Phase 3 details with ocrelizumab in relapsing MS and PPMS are digested from recent presentations at ECTRIMS.
Aschoff wrote, “There is a growing awareness of the relevance of B cells in MS, and ocrelizumab has clearly validated that B cells are central to MS’s underlying biology. The longer term therapy required in MS, also requires treatments to achieve a higher safety threshold, and TG-1101 doses used in MS would be much lower than those used in lymphoma. We also note the August acquisition of the remaining ofatumumab rights by Novartis, and strongly view it to be inferior to TG-1101.” Novartis paid GSK $300 million upfront, and will pay $200 million upon starting Phase 3, and may make milestone payments up to $534 million, in addition to an up to 12% royalty on ofatumumab sales in autoimmune disease. The $500 million to be paid just to start Phase 3 in MS amounts to the vast majority of TG’s market cap, and that that sum is for just the remaining rights that Novartis did not own to what we view as a clearly inferior antibody.”
According to TipRanks.com, analyst Jonathan Aschoff has a total average return of -2.4% and a 37.6% success rate. Aschoff has a -6.7% average return when recommending TGTX, and is ranked #3436 out of 3775 analysts.
All the 4 analysts polled by TipRanks rate TG Therapeutics stock a Buy. With a return potential of 106%, the stock’s consensus target price stands at $26.25.
Don’t be late to the party – Click Here to see what 4500 Wall Street Analysts say about your stocks.